Nothing said here yet.
to join the conversation.
| Xu ZhenyuChief Scientific Officer | Sell | 4,000 | $28.7K | Tue, Oct 13 |
| Camblong JurgiExecutive Chairman | Sell | 8,500 | $61.7K | Mon, Oct 12 |
| Menu PhilippeChief Medical Officer | Sell | 5,000 | $36.3K | Mon, Oct 12 |
| Camblong JurgiExecutive Chairman | Sell | 40,172 | $326.5K | Mon, Oct 5 |
| Muken RossChief Executive Officer | Sell | 9,838 | $80.0K | Mon, Oct 5 |
| Menu PhilippeChief Medical Officer | Sell | 7,394 | $60.1K | Mon, Oct 5 |
| Xu ZhenyuChief Scientific Officer | Sell | 7,394 | $60.1K | Mon, Oct 5 |
| Van Well DaanChief Legal Officer | Sell | 6,168 | $50.1K | Mon, Oct 5 |
| Verma AbhimanyuChief Technology Officer | Sell | 5,284 | $42.9K | Mon, Oct 5 |
| Valente ManuelaChief People Officer | Sell | 4,240 | $34.5K | Mon, Oct 5 |
| CARDOZA GEORGEChief Financial Officer | Sell | 1,592 | $12.9K | Mon, Oct 5 |
| Puylaert KevinChief Sales Officer | Sell | 185 | $1.5K | Mon, Oct 5 |
SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca…
Companies sign MOU to explore collaboration on deployable structures, spacecraft integration and scalable architectures for in-orbit Artificial Intelligence and edge computing LAS VEGAS, Sept.
SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Citigroup has appointed veteran banker Sophia Wang as a managing director and head of China financial-institutional sales and senior relationship management (SRM), marking the latest move by the Wall Street lender to deepen its footprint in mainland capital markets despite ongoing geopolitical friction.
SOPHiA GENETICS is back in focus as analysts reset their central price views, with fair value moving from US$9.00 to US$9.75.
Revenue jumped 27% as platform volume surged and biopharma partnerships accelerated.
SOPHiA GENETICS is tasked with developing its Solid Tumor application as a decentralised companion diagnostic.
Sophia Genetics SA (SOPH) delivers 27% revenue growth, raises full-year guidance, and announces landmark AstraZeneca CDX deals and MSK joint venture.
SOPHiA GENETICS (NASDAQ:SOPH) reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements.